Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 175,916 shares, a decrease of 95.4% from the November 30th total of 3,784,612 shares. Currently, 8.9% of the shares of the stock are short sold. Based on an average trading volume of 444,086 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 444,086 shares, the short-interest ratio is currently 0.4 days. Currently, 8.9% of the shares of the stock are short sold.

Moleculin Biotech Trading Down 1.8%

Shares of MBRX traded down $0.07 during trading hours on Friday, hitting $3.83. The company had a trading volume of 89,021 shares, compared to its average volume of 208,108. The company has a market capitalization of $7.81 million, a PE ratio of -0.12 and a beta of 1.58. Moleculin Biotech has a one year low of $3.63 and a one year high of $91.25. The company’s fifty day moving average price is $8.91 and its two-hundred day moving average price is $11.63.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.07. Analysts forecast that Moleculin Biotech will post -7.98 earnings per share for the current year.

Institutional Trading of Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC lifted its position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,250,000 shares of the company’s stock after purchasing an additional 932,414 shares during the quarter. Armistice Capital LLC owned 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MBRX has been the subject of a number of recent research reports. Roth Capital reiterated a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective (up from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Wall Street Zen downgraded shares of Moleculin Biotech to a “strong sell” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.